CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer

Um, Sung Ho, Mundi, Neil, Yoo, John, Palma, David A, Fung, Kevin, MacNeil, Danielle, Wehrli, Bret, Mymryk, Joe S, Barrett, John W, Nichols, Anthony C·2014·Journal of Clinical Virology
DOI 10.1016/j.jcv.2014.06.019
Open this paper in CoChat — free account

Abstract

Background The role of the HPV E6/E7 oncogenes in head and neck squamous cell cancer (HNSCC) has been studied extensively, but the role of the viral E5 protein remains poorly understood. Studies in cervical cancer indicate that E5 increases epidermal growth factor receptor (EGFR) recycling to the cell surface and enhances growth factor signal transduction. Objective This study was designed to examine the relationship between HPV E5, EGFR, and survival in HPV-positive HNSCC. Study design A retrospective search of the London Health Sciences Centre pathology database was performed to identify oropharyngeal cancer samples. HPV E5 and EGFR expression was measured by reverse transcriptase real-time PCR. Results The majority of oropharyngeal tumor samples (59/82, 72%) were HPV-16 positive. Among the HPV-positive tumors, highly variable E5 expression was detected from early polycistronic transcripts. Tumors with high E5 expression levels had significantly higher EGFR levels (p=0.03). High E5 levels were correlated with improved recurrence-free survival, but not overall survival (p=0.02 and 0.71, respectively), whereas high EGFR was strongly associated with decreased recurrence-free and overall survival (p Conclusions HPV E5-encoded transcripts are variably expressed in HPV-positive HNSCC and this is correlated with EGFR expression in HPV-positive OPC. However, E5 and EGFR independently predict recurrence-free survival in opposing manners. These findings require further validation to…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jcv.2014.06.019

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 35

  1. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 · DOI
  2. Chaturvedi, 2011, Human papillomavirus and rising oropharyngeal cancer incidence in the United States, J Clin Oncol, 29, 4294, 10.1200/JCO.2011.36.4596 · DOI
  3. Nichols, 2013, The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population, Curr Oncol, 20, 212, 10.3747/co.20.1375 · DOI
  4. Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Eng J Med, 363, 24, 10.1056/NEJMoa0912217 · DOI
  5. Gillison, 2004, Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity, Semin Oncol, 31, 744, 10.1053/j.seminoncol.2004.09.011 · DOI
  6. Jegu, 2013, Trends over three decades of the risk of second primary cancer among patients with head and neck cancer, Oral Oncol, 49, 9, 10.1016/j.oraloncology.2012.06.018 · DOI
  7. Price, 2012, Current treatment options for metastatic head and neck cancer, Curr Treat Options Oncol, 13, 35, 10.1007/s11864-011-0176-y · DOI
  8. Cardesa, 2011, Carcinoma of the head and neck in the HPV era, Acta dermatovenerol Alp Panonica Adriat, 20, 161
  9. O'Sullivan, 2013, Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis, J Clin Oncol, 31, 543, 10.1200/JCO.2012.44.0164 · DOI
  10. DiMaio, 2001, Mechanisms of cell transformation by papillomavirus E5 proteins, Oncogene, 20, 7866, 10.1038/sj.onc.1204915 · DOI
  11. Lewis, 2008, The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth, Virol J, 5, 30, 10.1186/1743-422X-5-30 · DOI
  12. Leechanachai, 1992, The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus, Oncogene, 7, 19
  13. Straight, 1995, The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes, J Virol, 69, 3185, 10.1128/JVI.69.5.3185-3192.1995 · DOI
  14. Chung, 2009, Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications, Clin Cancer Res, 15, 6758, 10.1158/1078-0432.CCR-09-0784 · DOI
  15. Lorenzon, 2011, In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix, J Clin Virol, 52, 79, 10.1016/j.jcv.2011.06.007 · DOI
  16. Gold, 2009, Role of molecular markers and gene profiling in head and neck cancers, Curr Opin Oncol, 21, 206, 10.1097/CCO.0b013e328329ac00 · DOI
  17. Zhu, 2013, Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis, J Surg Oncol, 10.1002/jso.23406 · DOI
  18. Kumar, 2008, EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer, J Clin Oncol, 26, 3128, 10.1200/JCO.2007.12.7662 · DOI
  19. Nichols, 2013, Does HPV type affect outcome in oropharyngeal cancer?, J Otolaryngol Head Neck Surg, 42, 9, 10.1186/1916-0216-42-9 · DOI
  20. Fakhry, 2008, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J Natl Cancer Inst, 100, 261, 10.1093/jnci/djn011 · DOI
  21. Nichols, 2009, HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma, Otolaryngol – Head Neck Surg, 140, 228, 10.1016/j.otohns.2008.11.025 · DOI
  22. Nichols, 2011, Surgical salvage of the oropharynx after failure of organ-sparing therapy, Head Neck, 33, 516, 10.1002/hed.21480 · DOI
  23. Dimaio, 2013, The E5 proteins, Virology, 445, 99, 10.1016/j.virol.2013.05.006 · DOI
  24. Huotari, 2011, Endosome maturation, EMBO J, 30, 3481, 10.1038/emboj.2011.286 · DOI
  25. Suprynowicz, 2010, The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification, J Virol, 84, 10619, 10.1128/JVI.00831-10 · DOI
  26. Straight, 1993, The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes, J Virol, 67, 4521, 10.1128/JVI.67.8.4521-4532.1993 · DOI · Paper page
  27. Pim, 1992, Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor, Oncogene, 7, 27
  28. Normanno, 2006, Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, 366, 2, 10.1016/j.gene.2005.10.018 · DOI
  29. Genther Williams, 2005, Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene, Cancer Res, 65, 6534, 10.1158/0008-5472.CAN-05-0083 · DOI · Paper page
  30. DiGiovanna, 1998, Active signaling by Neu in transgenic mice, Oncogene, 17, 1877, 10.1038/sj.onc.1202091 · DOI
  31. Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer, 37, S9, 10.1016/S0959-8049(01)00231-3 · DOI
  32. Kalyankrishna, 2006, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol, 24, 2666, 10.1200/JCO.2005.04.8306 · DOI
  33. Nichols, 2013, Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial, BMC Cancer, 13, 133, 10.1186/1471-2407-13-133 · DOI
  34. Quon, 2012, Treatment deintensification strategies for HPV-associated head and neck carcinomas, Otolaryngol Clin North Am, 45, 845, 10.1016/j.otc.2012.04.007 · DOI
  35. O'Sullivan, 2012, Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation, Radiother Oncol, 103, 49, 10.1016/j.radonc.2012.02.009 · DOI

Cited by

See all 31

Metadata

Authors
Um, S. H., Mundi, N., Yoo, J., Palma, D. A., Fung, K., MacNeil, D., Wehrli, B., Mymryk, J. S., Barrett, J. W., & Nichols, A. C.
Venue
Journal of Clinical Virology
Publisher
Elsevier BV
Published
2014-09
Volume
61
Issue
1
Pages
94-100
ISSN
1386-6532
DOI
10.1016/j.jcv.2014.06.019
Cited by
31
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review